The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial
Table 1
Demographic and clinical characteristics of participants with different baseline ASCVD risk scores.
Characteristics
ASCVD below 7.5%
ASCVD equal to or greater than 7.5% and less than 10%
ASCVD equal to or greater than 10% and less than 15%
ASCVD equal to or greater than 15%.
Intensive
Standard
Intensive
Standard
Intensive
Standard
Intensive
Standard
N
438 (9.4)
431 (9.2)
396 (8.5)
385 (8.2)
936 (20.0)
953 (20.4)
2908 (62.2)
2914 (62.2)
ASCVD%
5.44 ± 1.43
5.41 ± 1.53
8.84 ± 0.73
8.73 ± 0.73
12.49 ± 1.45
12.48 ± 1.41
30.16 ± 13.75
30.07 ± 13.59
Age, y
57.35 ± 4.24
57.07 ± 4.42
60.26 ± 4.80
59.81 ± 5.02
62.25 ± 5.68
62.35 ± 5.75
72.39 ± 8.35
72.40 ± 8.40
Female
298 (17.7)
288 (17.5)
207 (12.3)
194 (11.8)
345 (20.5)
337 (20.4)
834 (49.5)
829 (50.3)
Smoking status
Never
237 (13.3)
252 (12.2)
230 (9.9)
199 (9.6)
435 (21.2)
443 (21.4)
1139 (55.6)
1178 (56.9)
Former
134 (6.8)
149 (7.5)
154 (7.8)
148 (7.4)
377 (19.1)
397 (19.9)
1312 (66.4)
1302 (65.2)
Current
31 (4.9)
30 (5.0)
39 (6.1)
38 (6.3)
123 (19.2)
112 (18.6)
867 (69.9)
446 (69.8)
SBP, mmHg
131.1 ± 14.5
129.9 ± 14.1
133.3 ± 13.6
133.6 ± 13.3
136.5 ± 14.7
136.7 ± 13.9
142.8 ± 15.5
142.8 ± 15.2
DBP, mmHg
80.6 ± 10.7
80.0 ± 10.9
80.2 ± 11.0
80.3 ± 10.3
80.5 ± 11.0
80.5 ± 11.3
76.8 ± 12.2
78.0 ± 12.3
BMI, kg/m2
31.9 ± 6.7
31.9 ± 6.4
31.5 ± 6.2
31.4 ± 6.8
30.9 ± 6.2
30.9 ± 5.7
29.0 ± 5.2
28.8 ± 5.2
TC, mg/dL
195.5 ± 42.7
194.7 ± 44.3
194.7 ± 41.1
192.8 ± 37.7
191.8 ± 40.7
190.4 ± 40.3
188.2 ± 41.3
188.8 ± 40.9
HDL, mg/dL
54.7 ± 15.3
55.0 ± 14.9
53.2 ± 15.1
53.2 ± 14.4
52.1 ± 12.9
51.9 ± 14.0
52.9 ± 14.4
52.7 ± 14.7
TG, mg/dL
123.8 ± 64.9
125.9 ± 79.4
124.4 ± 66.0
119.4 ± 67.6
124.0 ± 102.0
127.9 ± 87.5
125.2 ± 85.1
128.0 ± 102.2
Glucose, mg/dL
96.9 ± 10.8
97.4 ± 10.6
98.3 ± 11.7
96.7 ± 11.4
97.8 ± 12.6
98.2 ± 11.6
99.5 ± 14.6
99.4 ± 14.4
ALCR, mg/g
24.9 ± 84.1
35.1 ± 140.9
24.5 ± 75.6
32.3 ± 148.3
35.8 ± 177.9
39.3 ± 183.2
52.2 ± 197.7
43.7 ± 144.0
EGFR
75.6 ± 20.5
75.1 ± 21.6
75.3 ± 22.0
77.4 ± 21.0
76.6 ± 20.9
74.8 ± 19.7
69.0 ± 19.9
69.4 ± 20.1
CKD history
90 (6.8)
96 (7.3)
91 (6.8)
71 (5.4)
185 (13.9)
198 (15.0)
968 (72.5)
951 (72.3)
CVD history
80 (8.5)
79 (5.4)
64 (6.8)
63 (6.7)
140 (14.9)
175 (18.7)
656 (69.8)
620 (66.2)
N_AGENTS
0
68 (15.7)
46 (10.0)
53 (12.3)
52 (11.6)
111 (25.7)
121 (26.9)
200 (46.3)
232 (51.6)
1
136 (10.0)
124 (8.9)
118 (8.6)
113 (8.1)
254 (18.6)
263 (18.9)
857 (62.8)
888 (64.0)
2
131 (7.9)
168 (10.3)
140 (8.4)
127 (7.8)
322 (19.3)
307 (18.9)
1072 (64.4)
1025 (63.0)
3
79 (8.3)T
77 (8.0)
70 (7.3)
74 (7.7)
195 (20.4)
196 (20.3)
612 (64.0)
617 (64.0)
4
23 (9.1)
17 (7.0)
15 (5.9)
17 (7.0)
54 (21.3)
65 (26.6)
161 (63.6)
154 (59.4)
5
1 (16.7)
0
0
2 (20)
0
1 (10)
5 (83.3)
7 (70.0)
6
0
0
0
0
0
0
1 (100)
0
Statin
153 (7.7)
167 (8.0)
147 (7.4)
134 (6.5)
357 (18.0)
400 (19.3)
1321 (66.8)
1375 (66.2)
Data were presented as mean ± SD or number (%) for continuous and categorical variables, respectively. ASCVD: Atherosclerotic Cardiovascular Disease, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, TC: total cholesterol, HDL: high density lipoprotein, TG: triglycerides, ALCR: albumin-to-creatinine ratio, EGFR: estimated glomerular filtration rate, CKD: chronic kidney disease, CVD: cardiovascular disease, N_AGENTS: number of antihypertensive agents.
